Abstract
Cerebral hypometabolism and abnormal levels of amyloid beta (Aβ), total (t-tau) and phosphorylated tau (ptau) proteins in cerebrospinal fluid (CSF) are established biomarkers of Alzheimers disease (AD). We examined the agreement between these biomarkers in a single center study of patients with AD of severity extending over a wide range. Forty seven patients (MMSE 21.4±3.6, range 13-28 points) with incipient and probable AD underwent positron emission tomography with [18F]-fluorodeoxyglucose (FDG-PET) and lumbar puncture for CSF assays of Aβ1-42, p-tau181, and t-tau. All findings were classified as either positive or negative for AD. Statistical analyses were performed for the whole sample (n=47) and for the subgroups stratified as mild (MMSE > 20 points, n=30) and moderate (MMSE < 21 points, n=17) AD. In the whole patient sample, the agreement with the FDG-PET finding was 77% (chance-corrected kappa [κ]=0.34, p=0.016) for t-tau, 68% (κ=0.10, n.s.) for p-tau181, and 68% (κ=0.04, n.s.) for Aβ1-42. No significant agreement was found in the mild AD subgroup, while there was a strong agreement for t-tau (94%, κ=0.77, p=0.001) and p-tau181 (88%, κ=0.60, p=0.014) in the moderate AD group. A significant agreement between the FDG-PET and CSF tau findings in patients with AD supports the view that both are markers of neurodegeneration. CSF tau proteins and FDG-PET might substitute each other as supportive diagnostic tools in patients with suspected moderate-to-severe Alzheimers dementia, while this is not the case in subjects at an earlier disease stage.
Keywords: Amyloid, biomarker, CSF, dementia, mild cognitive impairment, positron emission tomography, tau, ApoE
Current Alzheimer Research
Title: Stage-Dependent Agreement between Cerebrospinal Fluid Proteins and FDG-PET Findings in Alzheimer's Disease
Volume: 9 Issue: 2
Author(s): Igor Yakushev, Matthias J. Muller, Hans-Georg Buchholz, Ulrike Lang, Heidi Rossmann, Harald Hampel, Mathias Schreckenberger and Andreas Fellgiebel
Affiliation:
Keywords: Amyloid, biomarker, CSF, dementia, mild cognitive impairment, positron emission tomography, tau, ApoE
Abstract: Cerebral hypometabolism and abnormal levels of amyloid beta (Aβ), total (t-tau) and phosphorylated tau (ptau) proteins in cerebrospinal fluid (CSF) are established biomarkers of Alzheimers disease (AD). We examined the agreement between these biomarkers in a single center study of patients with AD of severity extending over a wide range. Forty seven patients (MMSE 21.4±3.6, range 13-28 points) with incipient and probable AD underwent positron emission tomography with [18F]-fluorodeoxyglucose (FDG-PET) and lumbar puncture for CSF assays of Aβ1-42, p-tau181, and t-tau. All findings were classified as either positive or negative for AD. Statistical analyses were performed for the whole sample (n=47) and for the subgroups stratified as mild (MMSE > 20 points, n=30) and moderate (MMSE < 21 points, n=17) AD. In the whole patient sample, the agreement with the FDG-PET finding was 77% (chance-corrected kappa [κ]=0.34, p=0.016) for t-tau, 68% (κ=0.10, n.s.) for p-tau181, and 68% (κ=0.04, n.s.) for Aβ1-42. No significant agreement was found in the mild AD subgroup, while there was a strong agreement for t-tau (94%, κ=0.77, p=0.001) and p-tau181 (88%, κ=0.60, p=0.014) in the moderate AD group. A significant agreement between the FDG-PET and CSF tau findings in patients with AD supports the view that both are markers of neurodegeneration. CSF tau proteins and FDG-PET might substitute each other as supportive diagnostic tools in patients with suspected moderate-to-severe Alzheimers dementia, while this is not the case in subjects at an earlier disease stage.
Export Options
About this article
Cite this article as:
Yakushev Igor, J. Muller Matthias, Buchholz Hans-Georg, Lang Ulrike, Rossmann Heidi, Hampel Harald, Schreckenberger Mathias and Fellgiebel Andreas, Stage-Dependent Agreement between Cerebrospinal Fluid Proteins and FDG-PET Findings in Alzheimer's Disease, Current Alzheimer Research 2012; 9 (2) . https://dx.doi.org/10.2174/156720512799361592
DOI https://dx.doi.org/10.2174/156720512799361592 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Compartmentalized Platforms for Neuro-Pharmacological Research
Current Neuropharmacology Natural History of Ulcerative Colitis: Current Knowledge
Current Drug Targets Recent Achievements on Siderophore Production and Application
Recent Patents on Biotechnology Hypoxia and Fetal Heart Development
Current Molecular Medicine Subclinical Hypothyroidism and Homeostatic Disturbances: Case Report and Literature Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Analgesic Considerations for Liver Transplantation Patients
Current Clinical Pharmacology Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
Current Genomics The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry The Immunomodulatory Potential of Selected Bioactive Plant-Based Compounds in Breast Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Rare Pentoses Using Microbial and Enzymatic Reactions
Current Organic Chemistry Do Drugs Work for ΟΑΒ Following Prostate Cancer Surgery
Current Drug Targets Bacterial Siderophores and Their Potential Applications: A Review
Current Molecular Pharmacology Tissue Distribution and Pharmacodynamics of Rivastigmine after Intranasal and Intravenous Administration in Rats
Current Alzheimer Research The Critical Role of Insulin-Like Growth Factor-1 Isoforms in the Physiopathology of Skeletal Muscle
Current Genomics Comprehensive Profiling of the Low Molecular Weight Proteins and Peptides in Weak Cation Exchange Beads Human Serum Retentate
Protein & Peptide Letters Ultrasound-Induced Blood-Brain Barrier Opening
Current Pharmaceutical Biotechnology Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Nanomedicine